Goldenseal Sustainability & Cautions
Goldenseal (Hydrastis canadensis) is one of the most overharvested medicinal plants in North America — arguably the most overharvested woodland herb in the entire Western herbal tradition. CITES placed H. canadensis on Appendix II in 1997. The United Plant Savers organization lists goldenseal on its "At-Risk" register, the most urgent botanical conservation category. Twelve or more U.S. states list goldenseal as endangered, threatened, or vulnerable under state-level statutes. Wild populations have collapsed by approximately 50% over the past century, driven by the combination of intensive wildcrafting for the medicinal trade and the loss of the mature deciduous-forest habitat that goldenseal requires. Three points shape the ethical use of goldenseal today: cultivated and Forest Grown Verified material leaves wild populations untouched, while wild-crafted root draws on them; cheaper and more abundant berberine sources (Oregon grape, barberry, purified berberine hydrochloride (HCl)) cover the uses that do not depend on goldenseal's unique alkaloid profile; and the strict pregnancy/neonatal contraindications and the extensive drug-interaction profile make goldenseal one of the more hazardous "natural" herbs on the shelf. This deep-dive walks through the full conservation story, the decision framework for choosing between goldenseal and alternatives, the certification systems that allow ethical sourcing, and the complete safety profile.
Table of Contents
- A Century of Overharvest — How We Got Here
- CITES Appendix II Listing (1997)
- United Plant Savers "At-Risk" Designation
- State-Level Endangered, Threatened, and Vulnerable Listings
- The Habitat Problem — Mature Hardwood Forest Loss
- Cultivated vs Woods-Grown vs Wild-Crafted
- Forest Grown Verified (FGV) Certification
- Oregon Grape, Barberry, and Pure Berberine Hydrochloride as Alternatives
- How Goldenseal Compares With Other Berberine Sources, Use by Use
- Pregnancy, Breastfeeding, and Neonatal Contraindications
- Drug Interactions (CYP450 and P-Glycoprotein)
- Other Cautions (Hypertension, Hypoglycemia, Duration, Children)
- Sourcing Markers — Signs of Cultivated and of Wild-Harvested Goldenseal
- Key Research Papers
- Connections
- Featured Videos
A Century of Overharvest — How We Got Here
The decline of wild goldenseal is a multigenerational story that begins with the rapid adoption of Hydrastis canadensis by 19th-century American medicine. European settlers learned about goldenseal from Native American practitioners in the late 18th century. By the 1830s, the Eclectic physicians had elevated goldenseal to one of their most frequently prescribed remedies. By the 1850s, professional goldenseal "diggers" were systematically combing the Appalachian and Ozark hardwood forests for marketable wild root, supplying a national trade that increasingly exported to Europe.
The pressure on wild populations intensified through several waves:
- 1830s-1900s — rise of Eclectic medicine drives the first surge in commercial wild harvest, particularly from West Virginia, eastern Kentucky, Tennessee, and North Carolina
- 1900s-1940s — goldenseal remains a USP-official drug, sustaining steady commercial demand even as overall botanical-medicine prescriptions decline. Combined with timber harvest and clearing for agriculture, wild populations continue to shrink.
- 1970s-1990s — the rise of the modern herbal-supplement industry produces a second major surge in goldenseal demand. By the 1990s, the United States is producing approximately 200,000 to 400,000 pounds of dried goldenseal root per year, the vast majority still wild-harvested.
- 1990s-2000s — conservation groups including United Plant Savers begin actively documenting the wild-population collapse. CITES Appendix II listing in 1997. State-level endangered-species statutes begin to proliferate.
- 2000s-present — gradual shift toward cultivated and woods-grown supply, though wild harvest continues at significant levels. Forest Grown Verified certification launched 2014. Cultivated goldenseal now comprises a growing fraction of supply but wild-harvested material is still widely sold.
The cumulative effect of nearly 200 years of intensive wild harvest, layered onto the parallel loss of mature deciduous-forest habitat across the eastern United States, has produced documented declines of 50% or more in wild population density across goldenseal's native range. The species is not extinct in the wild, but it is significantly more rare than it was a century ago, and remaining wild populations are concentrated in increasingly fragmented forest patches.
CITES Appendix II Listing (1997)
The Convention on International Trade in Endangered Species of Wild Fauna and Flora (CITES) is a multilateral treaty, in force since 1975 and now with 185 parties, that regulates international trade in species whose survival is threatened by commercial trade. Species are listed on one of three Appendices according to the level of protection required.
Appendix I includes species threatened with extinction; international commercial trade is generally prohibited.
Appendix II includes species not necessarily threatened with extinction but in which trade must be controlled to ensure that wild populations are not threatened. Trade is allowed but only with CITES-issued export permits, and the exporting country must conclude (and document) that the export is not detrimental to the species' survival.
Appendix III includes species protected in at least one country which has asked other CITES parties for assistance in controlling trade.
Hydrastis canadensis was added to CITES Appendix II at the Tenth Conference of the CITES Parties in June 1997 (effective September 18, 1997), on a proposal submitted by the United States; the U.S. Fish and Wildlife Service cites concern about over-collection of wild goldenseal in the United States and Canada, where the plant grows. The listing was motivated by documented declines in wild populations, the increasing volume of international trade (particularly to European, Asian, and other markets), and the difficulty of distinguishing cultivated from wild-harvested material once roots had been dried and processed.
Practical effects of the CITES listing:
- The listing covers live plants and whole or sliced roots and parts of roots only; it excludes manufactured parts or derivatives such as powders, pills, extracts, tonics, teas and confectionery (U.S. Fish and Wildlife Service notice, Federal Register, 1999). Exports of the listed plants and roots require a CITES export permit issued by the country of origin (the U.S. Fish and Wildlife Service for U.S.-sourced material), while finished retail products in those excluded forms need no CITES permit.
- Each export must be documented as non-detrimental to wild populations — cultivated material qualifies straightforwardly; wild-harvested material requires the exporting country to demonstrate sustainable harvest practices
- Domestic US sale is not directly regulated by CITES, but the listing has spurred state-level regulation and industry self-regulation
- The listing creates a paper trail that allows tracing the supply chain for ethically sourced goldenseal
The CITES listing has been broadly successful in slowing the international export trade of wild goldenseal, though it has not eliminated the domestic US wild-harvest pressure on the remaining wild populations.
United Plant Savers "At-Risk" Designation
United Plant Savers (UpS) is a nonprofit organization founded in 1994 by herbalist Rosemary Gladstar and a coalition of botanical-medicine practitioners, conservationists, and academic ethnobotanists. Its mission is to protect native medicinal plants of North America and their natural habitats. The organization maintains two principal lists:
- "At-Risk" list — the most urgent conservation category. Includes species that are in significant decline due to overharvest, habitat loss, or both, and that warrant immediate conservation action by herbalists, consumers, and regulators.
- "To-Watch" list — species that are not yet in critical decline but that are sufficiently in demand and sufficiently vulnerable to require ongoing monitoring.
Hydrastis canadensis has been on the United Plant Savers "At-Risk" list since the organization's founding in 1994, and remains a centerpiece of UpS conservation advocacy. The organization operates the Goldenseal Botanical Sanctuary in Ohio — a 379-acre forest reserve dedicated specifically to protecting and propagating goldenseal and other at-risk woodland medicinals — and certifies certain cultivated suppliers as meeting UpS sustainability standards.
Other At-Risk species sharing the list with goldenseal include American ginseng (Panax quinquefolius), black cohosh (Actaea racemosa), blue cohosh (Caulophyllum thalictroides), bloodroot (Sanguinaria canadensis), echinacea species (E. angustifolia in particular), helonias root (Chamaelirium luteum), ladyslipper orchids, lomatium, osha, partridge berry, pink ladyslipper, ramps, sandalwood, slippery elm, sundew, trillium species, true unicorn, Venus flytrap, white sage, and wild yam. The breadth of the list reflects the broader crisis facing North American medicinal woodland flora.
The United Plant Savers framework offers consumers a clear ethical standard: prefer cultivated material from any At-Risk species, support Forest Grown Verified suppliers when available, and substitute non-threatened alternatives when therapeutically appropriate.
State-Level Endangered, Threatened, and Vulnerable Listings
In addition to the federal CITES listing, more than a dozen U.S. states have placed Hydrastis canadensis on state-level endangered, threatened, or vulnerable species lists. The specific designation varies by state, but the practical effect is restrictions or prohibitions on wild harvest, transportation, and sale of state-origin wild goldenseal.
States that list goldenseal as endangered, threatened, or otherwise of special conservation concern include:
- Connecticut — Endangered (Connecticut Endangered Species Act)
- Georgia — Unusual (state-protected)
- Maine — Endangered
- Maryland — Highly State Rare
- Massachusetts — Endangered (state MESA listing)
- Michigan — Threatened
- Minnesota — Endangered
- New Jersey — Endangered
- New York — Threatened
- North Carolina — Endangered (Plant Conservation Program)
- Tennessee — Threatened
- Vermont — Endangered
- Other states with regulatory or monitoring requirements: Ohio, Pennsylvania, West Virginia, Virginia, Indiana, Illinois
The strongest wild populations of goldenseal remain in Kentucky, West Virginia, Indiana, southern Ohio, and parts of Virginia and Tennessee. Even in these strongholds, wild populations are under sustained pressure from continued commercial wild harvest, and regulatory frameworks vary in their enforcement effectiveness.
For buyers, the spread of state-level listings adds to the conservation case against wild-harvested goldenseal. The chain of custody of wild-harvested root is practically impossible to verify and the rules differ from state to state; cultivated material carries neither problem.
The Habitat Problem — Mature Hardwood Forest Loss
Beyond the direct harvest pressure on goldenseal populations, the broader threat is habitat loss. Hydrastis canadensis is a understory perennial that requires very specific growing conditions:
- Deep shade from a mature hardwood canopy (oak-hickory, beech-maple, mixed mesophytic forest types) — goldenseal cannot tolerate full sun and grows poorly in young or disturbed forests
- Rich, well-drained, calcareous to neutral soil — typically associated with limestone-derived parent material and accumulated leaf litter
- Moist but not waterlogged conditions — well-drained slopes and bottomland margins, never standing water
- Mature forest ecosystem with mycorrhizal partners — goldenseal's root system depends on specific fungal associations that take decades to establish
- Minimal disturbance — goldenseal is extremely sensitive to logging, road construction, recreational trampling, and grazing
This habitat profile is essentially the inverse of what modern land-use trends have produced across the eastern United States. From 1800 to 1920, the original eastern hardwood forest was reduced by approximately 70% through clearing for agriculture and timber. From 1920 to present, regrowth has produced significant forest recovery in area but predominantly in the form of young, structurally simple, even-aged second-growth forest that lacks the mature canopy conditions goldenseal requires.
The current eastern US deciduous forest area is approximately 220 million acres, but mature (old-growth or near-old-growth) hardwood forest accounts for less than 1% of this total. Goldenseal's suitable habitat has been compressed into a small fraction of the area it occupied at European contact.
The habitat dimension of the goldenseal conservation problem is particularly significant because it cannot be reversed quickly. A clear-cut forest can theoretically be replanted, but the mature canopy + mycorrhizal community + soil profile + understory diversity that goldenseal requires takes 100-200 years to develop. A conservation strategy for goldenseal therefore involves not just protecting remaining wild populations and shifting to cultivated supply, but also long-term forest stewardship practices that allow mature forest conditions to gradually recover.
Cultivated vs Woods-Grown vs Wild-Crafted
The supply chain for medicinal goldenseal falls into three broad categories with very different sustainability profiles:
Wild-crafted (wild-harvested) — root dug from naturally occurring wild populations. This is the ethically problematic category. Even where wild harvest is legal under state law, it directly extracts from declining wild populations. There is no practical way for the consumer to verify that wild-harvested root was sustainably collected. Every purchase of wild-crafted root draws on wild stands that are already in decline.
Cultivated (field-grown) — root grown under artificial shade cloth, in raised beds with amended soil, on commercial farms. This is mass-produced cultivated supply, similar to most other commercial herbs. Alkaloid content can be acceptable but is typically lower than woods-grown or wild material because the artificial growing conditions do not perfectly reproduce the mature-forest microenvironment. Sustainable from a conservation perspective — no wild population is affected. The lower alkaloid content matters least where alkaloid concentration is not critical.
Woods-grown (also called "simulated wild" or "forest-cultivated") — root deliberately planted into existing mature hardwood forest understory under conditions that mimic wild growing habitat. The grower selects a suitable forest site, plants goldenseal rhizomes or seeds, manages light competition, and harvests after 4-8 years. Alkaloid content is comparable to wild-harvested material. It is the most sustainable form of goldenseal supply. Woods-grown systems also generate income from standing mature forest, creating economic incentives for landowners to preserve rather than clear-cut their forests.
In conservation terms the order is: woods-grown first, cultivated second, wild-crafted last. Suppliers of cultivated root typically document their sourcing on the label and on their website; when a vendor does not document where its goldenseal came from, the buyer has no way to tell cultivated from wild-harvested root.
Woods-grown goldenseal comes from United Plant Savers-affiliated growers, specialty herb growers and herb farms, and seed suppliers (for home growers). A regional sustainable-development cooperative also coordinates woods-grown supply from a network of small-scale growers in the Appalachian region.
Forest Grown Verified (FGV) Certification
The Forest Grown Verified (FGV) program, a voluntary third-party verification process for forest-grown botanicals, was established in 2014 by a certification organization with the support of United Plant Savers; in the summer of 2019 control of the program passed to United Plant Savers. It addresses the cultivated-vs-wild supply chain ambiguity that complicates ethical goldenseal sourcing.
The FGV standard requires:
- Forest cultivation — the goldenseal must be deliberately planted into existing mature forest understory (not field-cultivated)
- Chain of custody documentation — from the specific forest plot through processing to the retail product
- Sustainable forest management — the forest itself must be managed in a way consistent with long-term ecological health
- No wild harvest — FGV-certified product must come from intentionally planted populations, not naturally occurring wild stands within the forest plot
- Third-party verification — independent auditing of the farm and supply chain
FGV-certified product is the most sustainably defensible goldenseal currently available in commercial supply. The certification is gradually becoming more common as both growers and consumers recognize the value of the chain-of-custody documentation. On a product label, FGV certification is the most specific marker of sustainable sourcing.
Other relevant certifications that may appear on goldenseal products:
- U.S. Department of Agriculture (USDA) Organic — addresses pesticide use and soil management but does not specifically address wild-vs-cultivated
- Fair Wild — an international standard for sustainably wild-collected botanicals; not applicable to goldenseal in the United States where wild collection is the underlying problem
- UpS-certified — older designation from United Plant Savers, similar in intent to FGV but with somewhat different specific requirements
Oregon Grape, Barberry, and Pure Berberine Hydrochloride as Alternatives
For the majority of clinical indications where goldenseal is considered, a more sustainable alternative is equally effective. The key sustainable alternatives:
Oregon grape (Mahonia aquifolium and related species) is the closest functional substitute for goldenseal. Native to the Pacific Northwest United States and southwestern Canada, Oregon grape is abundant in the wild and easily cultivated. Its root contains 2-3% berberine plus a distinct supporting alkaloid profile (berbamine, oxyacanthine) that provides efflux-pump inhibition and broader antimicrobial activity. For nearly all gut, urinary, and skin antimicrobial indications, Oregon grape root tincture or extract substitutes for goldenseal without therapeutic loss. Approximately 1/4 to 1/3 the cost of goldenseal per equivalent dose.
Barberry (Berberis vulgaris and related species) is a widely cultivated and naturalized shrub (introduced from Europe; some populations are considered invasive in parts of North America). The root and bark contain 1.5-3% berberine plus berbamine, palmatine, and jatrorrhizine. Similar therapeutic profile to Oregon grape. The fact that some North American barberry populations are managed as invasive species means that using barberry root is actively beneficial for habitat conservation in some regions.
Chinese goldthread (Coptis chinensis) contains the highest natural berberine concentration of any commonly available source (5-8%), and is the dominant source plant for commercial berberine hydrochloride extraction. Cultivated extensively in China; commercial supply is sustainably produced from cultivated stocks. Less commonly available in the Western herbal market in whole-plant form but very common as the source of commercial berberine extract.
Purified berberine hydrochloride (capsules) — the most economical and most precisely dosed option. Berberine extracted from Coptis or Phellodendron, purified to pharmaceutical-grade isolated compound, typically sold in 500 mg capsules at $0.10-0.30 per dose. For any indication where the primary effect is berberine (which is the majority of clinical applications), purified berberine hydrochloride delivers the same compound at a measured dose and the lowest cost. Free of sustainability concerns because the source plants are cultivated and the extraction is efficient.
The therapeutic comparison table:
- Antimicrobial in gut: berberine hydrochloride = Oregon grape = barberry = goldenseal (all effective; they differ in sustainability)
- Blood sugar / metabolic: berberine hydrochloride is the clinical-trial standard; whole-plant sources also work
- Anti-inflammatory / NF-kB: berberine is the active component; all sources equivalent
- Mucous-membrane astringency: only goldenseal contains hydrastine; this is the narrow advantage that justifies goldenseal over alternatives
- Severe methicillin-resistant Staphylococcus aureus (MRSA) / efflux-resistance contexts: goldenseal's hydrastine + canadine combination has documented advantages in vitro; in vivo clinical translation is less clear
- Topical wound care: tradition favors goldenseal; Oregon grape is also used
How Goldenseal Compares With Other Berberine Sources, Use by Use
Putting the sustainability ethics together with the therapeutic alternatives, the uses fall into two groups:
Indications where the alternative berberine sources are equally or more effective (Oregon grape, barberry, or berberine hydrochloride serve the same purpose):
- Small intestinal bacterial overgrowth (SIBO) eradication and maintenance
- Acute bacterial diarrhea (E. coli, V. cholerae, Shigella)
- Traveler's diarrhea prophylaxis and treatment
- H. pylori adjunct therapy
- C. difficile adjunct therapy
- Blood sugar / metabolic syndrome / type 2 diabetes adjunct
- Anti-inflammatory / NF-kB-pathway indications
- Routine "natural antibiotic" use for self-limited common infections
- General bitter-tonic digestive stimulation (gentian, dandelion root, or wormwood are also effective)
Indications where goldenseal's full alkaloid profile may be genuinely warranted (and where cultivated or FGV goldenseal is the form that spares wild stands):
- Acute catarrhal mucous-membrane conditions with significant inflammation where hydrastine's mucous-membrane astringency provides meaningful additional benefit (e.g., severe acute postnasal drip with mucousy congestion, severe inflammatory bronchitis with excessive secretion)
- Topical wound care where the traditional multi-alkaloid profile + the historical clinical track record outweighs the alternatives
- Highly resistant Gram-positive infections in a context where the canadine + hydrastine efflux-pump-inhibitor combination is therapeutically meaningful
The conservation-minded approach in this second group is cultivated or FGV-certified goldenseal at the minimum effective dose for the shortest effective duration. No use in either group depends on wild-crafted root, since woods-grown root has alkaloid content comparable to wild-harvested material.
In short, goldenseal fits the role of a specialized tool more than that of a general-purpose herbal antibiotic. For "antibiotic-like" general use, the alternatives are described as equally effective and are far more sustainable. For the narrow set of conditions where the unique alkaloid profile actually matters, cultivated goldenseal is the form that does not draw on wild stands.
Pregnancy, Breastfeeding, and Neonatal Contraindications
Goldenseal is ABSOLUTELY CONTRAINDICATED in pregnancy and breastfeeding, and in infants of any age.
The pregnancy contraindication is based on multiple distinct mechanisms, any one of which is a reason for concern on its own:
- Uterine stimulation — berberine has documented uterine-contractile activity in both animal and ex vivo human uterine tissue studies. Use during pregnancy carries a risk of stimulating premature contractions, miscarriage, or preterm labor.
- Placental transfer — berberine crosses the placental barrier and can reach measurable concentrations in fetal tissues.
- Developmental toxicity in animals — in a 2006 developmental-toxicity study, high-dose berberine given to pregnant rats harmed the mothers (reduced weight gain) but not the fetuses; in pregnant mice, 33% of the treated mothers died, and average fetal weight per litter fell 5-6% with no change in the number of live young. The study reports lower fetal weight, not birth defects (Jahnke 2006).
- Bilirubin displacement — kernicterus risk — berberine displaces bilirubin from its albumin binding site. In the neonate, displaced bilirubin can cross the immature blood-brain barrier and deposit in the basal ganglia, producing irreversible kernicterus (bilirubin-induced encephalopathy). The risk is particularly acute in premature infants and in infants with any baseline hyperbilirubinemia. Use of berberine-containing products near term, or by lactating mothers in the immediate postpartum period, carries this risk for the neonate. The concern comes from a 1993 laboratory study: in test-tube experiments berberine pushed bilirubin off albumin about ten times more strongly than phenylbutazone (a known strong displacer), and daily berberine injections for one week in adult rats raised blood levels of unbound and total bilirubin. The study notes that the Chinese herb huanglian (Chinese goldthread, Coptis chinensis), whose major ingredient is berberine, had been reported to pose some risk of kernicterus among jaundiced newborn Chinese infants (Chan 1993).
- Hydrastine vasoconstriction — the secondary alkaloid in goldenseal, hydrastine, has mild vasoconstrictive activity that could theoretically reduce uteroplacental blood flow.
The lactation contraindication follows from the same mechanisms: berberine is excreted in breast milk in measurable concentrations, and the nursing infant's immature hepatic conjugation system cannot efficiently clear it. The concern therefore covers all berberine-containing products (goldenseal, Oregon grape, barberry, Chinese goldthread, purified berberine hydrochloride) during breastfeeding, and most of all in the immediate postpartum period.
The infant contraindication is absolute and covers all oral and topical goldenseal use under 2 years of age. The bilirubin displacement risk applies, and infant skin and mucous membranes also have higher absorption of topically applied compounds than adult skin. For infant infection or inflammation, safe pharmaceutical alternatives exist for essentially every indication.
Drug Interactions (CYP450 and P-Glycoprotein)
Goldenseal is one of the most drug-interaction-prone herbs in common use. Berberine is a potent inhibitor of multiple cytochrome P450 enzymes, which control the absorption, distribution, and clearance of a wide range of prescription drugs.
CYP450 enzyme inhibition — berberine inhibits:
- Cytochrome P450 3A4 (CYP3A4) — the most abundant hepatic and intestinal cytochrome P450. Substrate drugs include: statins (atorvastatin, simvastatin), calcium channel blockers (amlodipine, diltiazem, verapamil), immunosuppressants (cyclosporine, tacrolimus), antiretrovirals (most protease inhibitors), benzodiazepines (alprazolam, midazolam), opioids (fentanyl, oxycodone), warfarin, sildenafil, many others. Cytochrome P450 3A4 inhibition by berberine can raise blood levels of these drugs substantially.
- Cytochrome P450 2D6 (CYP2D6) — substrate drugs include: selective serotonin reuptake inhibitor (SSRI)/serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressants (fluoxetine, paroxetine, venlafaxine), beta-blockers (metoprolol, propranolol), opioids (codeine, tramadol — both prodrugs activated by cytochrome P450 2D6), antipsychotics (risperidone, aripiprazole), tamoxifen. Inhibition can reduce efficacy of prodrugs (codeine, tramadol, tamoxifen) and raise levels of active substrates.
- CYP2C9 — substrate drugs include: warfarin (the most critical interaction), phenytoin, sulfonylureas (glipizide, glyburide), nonsteroidal anti-inflammatory drugs (celecoxib, ibuprofen, naproxen). The warfarin interaction is potentially serious — goldenseal can substantially increase warfarin's anticoagulant effect.
Measured in people — in 16 healthy volunteers, 14 days of goldenseal raised blood levels of the test drug midazolam (a CYP3A probe) from 107.9 to 175.3 ng·h/ml (area under the curve) and lengthened its half-life from 2.01 to 3.15 hours (Gurley 2008). An earlier study in 12 healthy volunteers taking goldenseal for 28 days found about 40% inhibition of both CYP2D6 and CYP3A4/5 activity (Gurley 2005).
P-glycoprotein (P-gp) — P-gp is an efflux transporter in the gut wall and the blood-brain barrier. Drugs it carries include digoxin (a drug with a narrow therapeutic index), several chemotherapeutic agents (doxorubicin, paclitaxel, etoposide, vincristine), cyclosporine, tacrolimus, and others. In people, goldenseal had little measurable effect on it: in 20 healthy volunteers taking goldenseal (3,210 mg a day for 14 days), the only statistically significant change in digoxin was a 14% rise in its peak blood level, and the authors concluded that goldenseal is not a potent modulator of P-gp in the body (Gurley 2007). A 2021 study in 16 healthy volunteers found no effect of goldenseal on rosuvastatin or furosemide, two drugs carried by other transporters (Nguyen 2021).
Clinically significant interactions to flag:
- Warfarin — goldenseal can substantially increase the international normalized ratio (INR), the blood-clotting measure used to adjust warfarin doses.
- Cyclosporine and tacrolimus — goldenseal can raise blood levels to toxic ranges.
- Sulfonylureas and insulin — additive hypoglycemia risk from berberine's blood-glucose-lowering effect plus CYP2C9 inhibition raising sulfonylurea levels.
- Metformin — goldenseal lowered metformin blood exposure in 16 healthy adults (geometric mean ratio 0.77, where 1.00 means no change) without changing its half-life or kidney clearance (Nguyen 2021). In a 2025 crossover study of adults with type 2 diabetes already taking metformin (500-2,550 mg a day), the overall change was not clinically meaningful (ratio 0.93), but metformin exposure fell by about 20% at low doses (500-750 mg), 14% at moderate doses (1,000-1,500 mg) and 0% at high doses (2,000-2,550 mg); average HbA1c (a three-month blood-sugar measure) went from 6.8% to 6.5% during the study (Nguyen 2025).
- Statins — goldenseal can raise statin levels, increasing myalgia / rhabdomyolysis risk.
- Antiretrovirals — serious interaction risk with most protease inhibitors and non-nucleoside reverse transcriptase inhibitors.
- Calcineurin inhibitors in transplant patients — potentially life-threatening interaction.
In people, the measured effects are higher midazolam levels (CYP3A), about 40% inhibition of CYP2D6 and CYP3A4/5, and lower metformin exposure in healthy adults (see above). The interactions extend to all berberine sources — switching to Oregon grape, barberry, or purified berberine hydrochloride does not remove the drug-interaction profile; only the conservation cost differs.
Other Cautions (Hypertension, Hypoglycemia, Duration, Children)
- Hypertension — hydrastine, goldenseal's second alkaloid, has mild vasoconstrictive activity. The concern is greatest for people with uncontrolled, severe or rapidly worsening hypertension, or on several blood-pressure medicines.
- Hypoglycemia risk — berberine has significant glucose-lowering activity (comparable to metformin in some clinical trials). Patients on insulin, sulfonylureas, meglitinides, or other hypoglycemic medications may experience additive hypoglycemia (blood sugar falling too low).
- Duration of use — herbal practitioners limit continuous goldenseal use to about 3 weeks. Cycling protocols (2-3 weeks on, 1-2 weeks off) are their standard pattern for extended use, intended both to prevent gut microbiota disruption and to allow mucous membranes to recover from the strong astringent effect of the alkaloids.
- Children — the contraindication under 2 years of age is absolute (see above). For children 2-12, integrative-medicine practice describes reduced doses scaled to body weight and limited durations.
- Liver disease — because berberine is metabolized by the liver, significant liver impairment is a listed caution, with reduced doses or no goldenseal at all as the approaches described; liver function tests are the usual check during extended use in people with existing liver disease.
- Kidney disease — berberine and its metabolites are partially excreted through the kidneys. Advanced chronic kidney disease (CKD stage 4-5) is a relative contraindication.
- Microbiota disruption — berberine's broad antimicrobial action will kill commensal as well as pathogenic bacteria. Long-term use without microbiota-restorative support can produce dysbiosis. Practitioners pair extended berberine courses with a high-fiber diet, fermented foods, and sometimes intermittent probiotic support.
- Allergic reactions — uncommon but documented. Patients with known sensitivity to other Ranunculaceae family plants may be at higher risk.
- Photosensitivity — rarely reported; some patients may experience increased skin sensitivity to sunlight during extended use.
Sourcing Markers — Signs of Cultivated and of Wild-Harvested Goldenseal
Markers of cultivated or forest-grown sourcing:
- Forest Grown Verified (FGV) certification — the strongest single sustainability marker
- United Plant Savers-certified suppliers — alternative or complementary certification
- Explicit "cultivated" or "woods-grown" labeling on the product
- Documented chain of custody from grower to retailer on the supplier's website
- Standardization to berberine content (e.g., 5% berberine) for consistency between batches
- Suppliers who publish their goldenseal sourcing policy and explicitly state they do not buy wild-harvested material
- U.S. Department of Agriculture Organic certification as an additional quality indicator (though not a substitute for cultivated vs wild sourcing documentation)
Warning signs of wild-harvested or adulterated product:
- "Wild-crafted," "wild-harvested," or "wildcraft" labeling — for goldenseal specifically, this is the ethically problematic source
- No sourcing information on the label or website — a supplier that does not document where its goldenseal came from leaves no way to rule out wild harvest
- Very low prices — goldenseal is genuinely expensive to grow sustainably; suspiciously cheap goldenseal is often wild-harvested or adulterated
- Suppliers in regions with weak regulatory oversight or known wild-harvest pressure
- Products with unusually low berberine content (under 2%) — may indicate adulteration with other plant material
- "Goldenseal blend" or "goldenseal complex" products that may contain only trace amounts of actual goldenseal alongside cheaper filler herbs
Suppliers of cultivated or FGV-certified goldenseal include specialty herb growers and herb farms, larger herbal-products companies (for specific products), and other suppliers explicitly affiliated with United Plant Savers or holding FGV certification.
For most clinical uses, purified berberine hydrochloride capsules are the cheapest form of berberine and free of sustainability concerns; goldenseal's full alkaloid profile is described as warranted only for a few narrow uses (see above).
Key Research Papers
- Gurley BJ, Gardner SF, Hubbard MA, et al. (2005). In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther — PubMed PMID: 15900287
- Gurley BJ, Swain A, Barone GW, et al. (2007). Effect of goldenseal (Hydrastis canadensis) and kava kava (Piper methysticum) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos — PubMed PMID: 17079360
- Gurley BJ, Swain A, Hubbard MA, et al. (2008). Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo. Clin Pharmacol Ther — PubMed PMID: 17495878
- Nguyen JT, Tian DD, Tanna RS, et al. (2021). Assessing Transporter-Mediated Natural Product-Drug Interactions Via In vitro-In Vivo Extrapolation: Clinical Evaluation With a Probe Cocktail. Clin Pharmacol Ther — PubMed PMID: 33174626
- Nguyen JT, Arian CM, Tanna RS, et al. (2025). The Pharmacokinetic Interaction Between Metformin and the Natural Product Goldenseal Is Metformin Dose-Dependent: A Three-Arm Crossover Study in Adults With Type 2 Diabetes. Clin Transl Sci — PubMed PMID: 39943692
- Jahnke GD, Price CJ, Marr MC, et al. (2006). Developmental toxicity evaluation of berberine in rats and mice. Birth Defects Res B Dev Reprod Toxicol — PubMed PMID: 16634078
- Chan E. (1993). Displacement of bilirubin from albumin by berberine. Biol Neonate — PubMed PMID: 8513024
- U.S. Fish and Wildlife Service (1999). Convention on International Trade in Endangered Species of Wild Fauna and Flora (CITES); Listing of Goldenseal (Hydrastis canadensis) in Appendix II and its Implementation by the United States; Public Meeting. Federal Register 64 FR 20320 — govinfo.gov
- CITES Appendix II listing of Hydrastis canadensis (1997) and ongoing trade monitoring — PubMed
- United Plant Savers At-Risk list methodology and goldenseal listing — PubMed
- Wild goldenseal population genetics and decline documentation — PubMed
- Woods-grown / forest-grown goldenseal cultivation methodology — PubMed
- Berberine drug interactions and CYP450 inhibition profile — PubMed
- Goldenseal effects on P-glycoprotein and drug transporter activity — PubMed
- Berberine teratogenicity and uterine contractile effects — PubMed
- Berberine displacement of bilirubin from albumin (neonatal kernicterus risk) — PubMed
- Berberine + warfarin pharmacokinetic interaction studies — PubMed
- Comparative phytochemistry of Hydrastis canadensis, Mahonia aquifolium, Berberis vulgaris, Coptis chinensis — PubMed
- Sustainable alternatives to At-Risk medicinal plants: the substitution framework — PubMed
PubMed Topic Searches
Connections
- All Herbs
- Goldenseal Overview
- Goldenseal Benefits Hub
- Goldenseal Antimicrobial Action
- Goldenseal for Digestive & Gut
- Goldenseal for Eye Health
- Berberine (Pure Supplement)
- Barberry (Sustainable Alternative)
- Berberine Remedy
- Echinacea
- Garlic
- Oregano
- Olive Leaf
- Myrrh
- Jaundice
- Staphylococcus Aureus
- Escherichia Coli
- Small Intestinal Bacterial Overgrowth
- Immune Boosting
- Gut Healing
- History